Headlands Technologies LLC Buys 2,883 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Headlands Technologies LLC raised its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 17.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,065 shares of the biopharmaceutical company’s stock after buying an additional 2,883 shares during the quarter. Headlands Technologies LLC’s holdings in Intra-Cellular Therapies were worth $1,592,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth approximately $96,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies during the third quarter valued at about $97,000. Quarry LP raised its stake in Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 1,300 shares during the period. Finally, Barlow Wealth Partners Inc. bought a new position in shares of Intra-Cellular Therapies in the 4th quarter worth $184,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Price Performance

Shares of Intra-Cellular Therapies stock opened at $131.87 on Wednesday. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.98. The firm’s 50-day moving average is $129.34 and its two-hundred day moving average is $100.60. The stock has a market cap of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ITCI shares. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research note on Friday, March 28th. They issued a “hold” rating for the company. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Piper Sandler reissued a “neutral” rating and issued a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Ten investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $106.08.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.